European venture capital firm Sofinnova Partners announced the promotion of Michael Krel to Partner of the Industrial Biotechnology team. Krel previously served as Principal on the team, where he focused on early-stage deals in Europe and North America.
BIH scientists optimise CRISPR gene scissors
Latest NewsTargeted genome editing using the CRISPR-Cas9 system is easy to use but far from being perfect. Computer calculated modification of CRISPR activity can reduce "off-target effects".
Azafaros BV raises €25m in Series A round
Latest NewsDutch biotech Azafaros B.V. has closed a €25m Series A financing round.
Researchers identify roots of childhood asthma
Latest NewsInfants who show defective immune responses to microbial components are more likely to acquire asthma later in childhood, according to a study of 541 children.
MaaT Pharma raise €18m to advance clinical pipeline
Latest NewsMaaT Pharma SA has announced €18m Series B financing to boost its microbiome biotherapeutics pipeline.
Centrient Pharmaceuticals: New CEO
AppointmentsEx-Sandoz Head of Global Franchises Rex Clements is taking over as CEO of Centrient Pharmaceuticals. Erstwhile Centrient CEO Karl Rotthier has decided to step down, the company said.
Valneva raises US$85m
Latest NewsFrench vaccine developer Valneva SA will raise $85m in a financing arrangement with Deerfield and OrbiMed and go Nasdaq to co-fund its Lyme disease programme.
EMA greenlights 15 new meds
Latest NewsThe EMA’s human medicines committee (CHMP) recommended fifteen medicines for approval at its January 2020 meeting.
Sofinnova: Industrial biotech promotion
AppointmentsEuropean venture capital firm Sofinnova Partners announced the promotion of Michael Krel to Partner of the Industrial Biotechnology team. Krel previously served as Principal on the team, where he focused on early-stage deals in Europe and North America.
European Biotechnology Guide 2020
Sponsored PublicationsThe 10th edition of the European Biotechnology Science & Industry Guide once more offers an interesting cross-section of the European biotech scene.
Sleeping sickness target deciphered
Latest NewsResearchers at the University of Luebeck have revealed the structure of the IMP dehydrogenase, a central target of T. brucei, which causes sleeping sickness.